2025
Early Compliance with Lung Cancer Lymph Node Standard 5.8: An Analysis of 2022 and 2023 Commission on Cancer Site Reviews
Baskin A, Funk E, Francescatti A, Sinco B, Palis B, Hieken T, Katz M, Boughey J, Weigel R, Dossett L, Boffa D. Early Compliance with Lung Cancer Lymph Node Standard 5.8: An Analysis of 2022 and 2023 Commission on Cancer Site Reviews. Journal Of Thoracic And Cardiovascular Surgery 2025 PMID: 40324749, DOI: 10.1016/j.jtcvs.2025.04.041.Peer-Reviewed Original ResearchCompliance ratePathology reportsQuality improvement toolsSite visitsSurgical lymph node evaluationSynoptic pathology reportingCurative-intent lung cancer resectionMedian percentageSupport hospitalLymph node evaluationLung cancer resectionImprovement toolsEligible sitesEligible casesEarly implementationSite complianceHilar stationMediastinal stationsNodal stagingCancer resectionLymph nodesCompliance dataImplementation of standardsVisitsNode evaluation
2020
Primary Treatment Selection for Clinically Node‐Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node‐Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial managementAssessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Park H, Young M, Olino K, Rahmati R, Mehra S, Burtness B, Judson B. Assessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1191-1192. DOI: 10.1016/j.ijrobp.2019.11.099.Peer-Reviewed Original Research
2018
Quality of Thoracic Lymph Node Evaluation in the Department of Defense According to the American College of Surgeons Commission on Cancer Surveillance Measure: Is There a Survival Benefit?
Heidenreich B, Durkee A, Bader J, Ahnfeldt E, Mase V. Quality of Thoracic Lymph Node Evaluation in the Department of Defense According to the American College of Surgeons Commission on Cancer Surveillance Measure: Is There a Survival Benefit? Journal Of The American College Of Surgeons 2018, 227: s185. DOI: 10.1016/j.jamcollsurg.2018.07.395.Peer-Reviewed Original Research
2017
Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer
Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Annals Of Surgical Oncology 2017, 24: 3073-3081. PMID: 28766195, DOI: 10.1245/s10434-017-5936-x.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalLN evaluationPositive breast cancerOverall survivalBreast cancerHormone receptor-positive breast cancerWomen Aged 70 YearsReceptor-positive breast cancerLymph node evaluationCancer-specific survivalLower hazard rateLN surgeryBetter OSPatient ageSEER databasePatient selectionTumor characteristicsSEER dataPatientsNode evaluationHormone receptorsCancerSurvivalTreatment variablesNCDB
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply